MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318280 | Name: Mirtazapine
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mirtazapine is an atypical antidepressant with noradrenergic and specific serotonergic activity. It works by blocking the α2 adrenergic auto- and heteroreceptors (enhancing serotonin release), and selectively antagonizing the 5-HT2 and 5-HT3 serotonin receptors in the central and peripheral nervous system. It also enhances serotonin neurotransmission at the 5-HT1 receptor and blocks the histaminergic (H1) and muscarinic receptors. Mirtazapine is not a serotonin or norepinephrine reuptake inhibitor.

Chemical Structure

Mirtazapine
Mirtazapine
CAS#85650-52-8 (free base)

Theoretical Analysis

MedKoo Cat#: 318280

Name: Mirtazapine

CAS#: 85650-52-8 (free base)

Chemical Formula: C17H19N3

Exact Mass: 265.1579

Molecular Weight: 265.35

Elemental Analysis: C, 76.95; H, 7.22; N, 15.84

Price and Availability

Size Price Availability Quantity
25mg USD 90.00 Ready to ship
50mg USD 150.00 Ready to ship
100mg USD 250.00 Ready to ship
200mg USD 425.00 Ready to ship
500mg USD 750.00 Ready to ship
1g USD 1,250.00 Ready to ship
2g USD 2,050.00 Ready to ship
5g USD 3,950.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
85650-52-8 (free base) 61337-67-5 (deleted) 1448014-35-4 (HCl) 868528-74-9 (HBr) 207516-99-2 (2HCl) 341512-89-8 (hemihydrate) 868363-97-7 (HBr) 207516-99-2 (HCl) 1216678-68-0 (deuterated forms d3)
Synonym
Mirtazapine, Remeron, Avanza, Axit, Mirtazon, Zispin, ORG-3770; ORG 3770; ORG3770;
IUPAC/Chemical Name
2-methyl-1,2,3,4,10,14b-hexahydrobenzo[c]pyrazino[1,2-a]pyrido[3,2-f]azepine
InChi Key
RONZAEMNMFQXRA-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
SMILES Code
CN1CCN2C(C3=CC=CC=C3CC4=C2N=CC=C4)C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# Mirtazapine [USAN:USP:INN:BAN]: 85650-52-8 Mirtazapine maleate: 85650-53-9 Mirtazapine hydrochloride: 207516-99-2 Mirtazapine hemihydrate: 341512-89-8 Mirtazapine maleate, (R)-: 680993-88-8
Biological target:
Mirtazapine (Org3770) is a potent and orally active noradrenergic and specific serotonergic antidepressant (NaSSA) agent.
In vitro activity:
To determine whether mirtazapine directly alters activation-induced inflammatory mediator production by human monocytes/macrophages, primary human CD14+ cells were isolated and treated in vitro with Con A, in presence or absence of mirtazapine. Incubation of healthy donor CD14+ monocytes with Con A in vitro resulted in a significant increase in culture supernatant levels of TNFα, IL-6, and the neutrophil-relevant chemokine CXCL5 (Figures 6A–C). Mirtazapine treatment significantly attenuated this Con A-induced increased production of these three mediators (Figures 6A–C). Reference: Front Immunol. 2019 Apr 12;10:803. https://pubmed.ncbi.nlm.nih.gov/31031775/
In vivo activity:
In freely moving rats, in the dorsal hippocampus, frontal cortex (FCX), nucleus accumbens and striatum, citalopram increased dialysate levels of 5-HT, but not dopamine (DA) and NA. On the contrary, mirtazapine markedly elevated dialysate levels of NA and, in FCX, DA, whereas 5-HT was not affected. Following 2 weeks administration, the facilitatory influence of mirtazapine upon dialysate levels of DA and NA versus 5-HT in FCX was maintained, and the influence of citalopram upon FCX levels of 5-HT versus DA and NA was also unchanged. Reference: Eur J Neurosci. 2000 Mar;12(3):1079-95. https://pubmed.ncbi.nlm.nih.gov/10762339/
Solvent mg/mL mM comments
Solubility
DMF 20.0 75.37
DMF:PBS (pH 7.2) (1:5) 0.2 0.60
DMSO 30.8 116.18
Ethanol 14.1 53.27
Water 26.8 101.13
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 265.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Park YS, Oh H, Sung KW. Atypical antidepressant mirtazapine inhibits 5-hydroxytryptamine3 receptor currents in NCB-20 cells. J Pharmacol Sci. 2023 Feb;151(2):63-71. doi: 10.1016/j.jphs.2022.12.002. Epub 2022 Dec 5. PMID: 36707180. 2. Almishri W, Shaheen AA, Sharkey KA, Swain MG. The Antidepressant Mirtazapine Inhibits Hepatic Innate Immune Networks to Attenuate Immune-Mediated Liver Injury in Mice. Front Immunol. 2019 Apr 12;10:803. doi: 10.3389/fimmu.2019.00803. PMID: 31031775; PMCID: PMC6474187. 3. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. doi: 10.1046/j.1460-9568.2000.00982.x. PMID: 10762339. 4. Haddjeri N, Blier P, de Montigny C. Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jan;355(1):20-9. doi: 10.1007/pl00004913. PMID: 9007838.
In vitro protocol:
1. Park YS, Oh H, Sung KW. Atypical antidepressant mirtazapine inhibits 5-hydroxytryptamine3 receptor currents in NCB-20 cells. J Pharmacol Sci. 2023 Feb;151(2):63-71. doi: 10.1016/j.jphs.2022.12.002. Epub 2022 Dec 5. PMID: 36707180. 2. Almishri W, Shaheen AA, Sharkey KA, Swain MG. The Antidepressant Mirtazapine Inhibits Hepatic Innate Immune Networks to Attenuate Immune-Mediated Liver Injury in Mice. Front Immunol. 2019 Apr 12;10:803. doi: 10.3389/fimmu.2019.00803. PMID: 31031775; PMCID: PMC6474187.
In vivo protocol:
1. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. doi: 10.1046/j.1460-9568.2000.00982.x. PMID: 10762339. 2. Haddjeri N, Blier P, de Montigny C. Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jan;355(1):20-9. doi: 10.1007/pl00004913. PMID: 9007838.
1: Kato M, Baba H, Takekita Y, Naito M, Koshikawa Y, Bandou H, Kinoshita T. Usefulness of mirtazapine and SSRIs in late-life depression: post hoc analysis of the GUNDAM study. Eur J Clin Pharmacol. 2023 Sep 13. doi: 10.1007/s00228-023-03563-8. Epub ahead of print. PMID: 37700038. 2: Zhou J, Zhao Y, Dai J, Zhang K. Environmentally relevant concentrations of antidepressant mirtazapine impair the neurodevelopment of zebrafish (Danio rerio). Ecotoxicol Environ Saf. 2023 Aug 8;262:115335. doi: 10.1016/j.ecoenv.2023.115335. Epub ahead of print. PMID: 37567106. 3: Barbosa-Méndez S, Salazar-Juárez A. Estradiol enhances the mirtazapine effects on the expression of cocaine-induced locomotor sensitization in female rats. Behav Pharmacol. 2023 Sep 1;34(6):362-374. doi: 10.1097/FBP.0000000000000743. Epub 2023 Aug 2. PMID: 37530137. 4: Almeida OLS, Ferriolli E, Taveira RCC, Rosenburg MG, Campanari DD, da Cruz Alves NM, Pfrimer K, Rapatoni L, Peria FM, Lima NKC. Mirtazapine versus Megestrol in the Treatment of Anorexia-Cachexia Syndrome in Patients with Advanced Cancer: A Randomized, Double-Blind, Controlled Phase II Clinical Trial. Cancers (Basel). 2023 Jul 12;15(14):3588. doi: 10.3390/cancers15143588. PMID: 37509249; PMCID: PMC10377007. 5: Kubera M, Arteta B, Grygier B, Curzytek K, Malicki S, Maes M. Stimulatory effect of fluoxetine and desipramine, but not mirtazapine on C26 colon carcinoma hepatic metastases formation: association with cytokines. Front Immunol. 2023 Jun 20;14:1160977. doi: 10.3389/fimmu.2023.1160977. PMID: 37409130; PMCID: PMC10318584. 6: Alharthy SA, Zughaibi TA, Vij P, Tabrez S, Almashjary MN, Alharthi S, Alamri T, Alghamdi BS, Harakeh S, Azhari SA, Farsi RM, Althagafy HS, Hassanein EHM. Mirtazapine attenuated cadmium-induced neuronal intoxication by regulating Nrf2 and NF-κB/TLR4 signals. Toxicol Mech Methods. 2023 Jul 4:1-13. doi: 10.1080/15376516.2023.2231530. Epub ahead of print. PMID: 37403423. 7: Ghazwani M, Vasudevan R, Kandasamy G, Manusri N, Devanandan P, Puvvada RC, Veeramani VP, Paulsamy P, Venkatesan K, Chidmabaram K, Dhurke R. Formulation of Intranasal Mucoadhesive Thermotriggered In Situ Gel Containing Mirtazapine as an Antidepressant Drug. Gels. 2023 Jun 2;9(6):457. doi: 10.3390/gels9060457. PMID: 37367128; PMCID: PMC10297899. 8: Gupta N, Gupta M. Diagnostic Overshadowing in High-Functioning Autism: Mirtazapine, Buspirone, and Modified Cognitive Behavioral Therapy (CBT) as Treatment Options. Cureus. 2023 May 24;15(5):e39446. doi: 10.7759/cureus.39446. PMID: 37362512; PMCID: PMC10289477. 9: Otsuki K, Tsukitaku M, Sato K, Sunami M, Inagaki M. A Case of Akathisia After Administration of a Very Low Dose of Mirtazapine. J Clin Psychopharmacol. 2023 Jul-Aug 01;43(4):378-379. doi: 10.1097/JCP.0000000000001708. Epub 2023 May 29. PMID: 37235510. 10: Umezaki Y, Motomura H, Egashira R, Toyofuku A, Naito T. A Case of Oral Cenesthopathy Treated With the Combination of Brexpiprazole and Mirtazapine. Clin Neuropharmacol. 2023 May-Jun 01;46(3):123-125. doi: 10.1097/WNF.0000000000000545. Epub 2023 Mar 10. PMID: 37191566. 11: Aslam H, Ahmed K, Iskander PA, Aloysius MM, Khurana V, Nasr S, Amjad MA. A Case of Mirtazapine-Induced Pancreatitis. Cureus. 2023 Apr 4;15(4):e37129. doi: 10.7759/cureus.37129. PMID: 37153315; PMCID: PMC10159629. 12: Huang CC, Kuo SC, Chen CY, Yeh YW. Hypereosinophilia and Cognitive Impairment Induced by Mirtazapine. Am J Ther. 2023 Apr 20. doi: 10.1097/MJT.0000000000001632. Epub ahead of print. PMID: 37097041. 13: Jamshidfar N, Hamdieh M, Eslami P, Batebi S, Sadeghi A, Rastegar R, Dooghaie Moghadam A, Masjedi Arani A. Comparison of the potency of nortriptyline and mirtazapine on gastrointestinal symptoms, the level of anxiety and depression in patients with functional dyspepsia. Gastroenterol Hepatol Bed Bench. 2023;16(1):468-477. doi: 10.22037/ghfbb.v16i1.2513. PMID: 37070114; PMCID: PMC10105507. 14: Šakić B, Greš A, Gajić Z. Mirtazapine-Induced Hyponatremia in a Patient with Systemic Mastocytosis and Generalized Anxiety Disorder. Psychiatr Danub. 2023 Spring;35(1):126-127. doi: 10.24869/psyd.2023.126. PMID: 37060606. 15: Dell'Osso L, Lorenzi P, Nardi B, Carpita B, Benedetti F, Cremone IM. Occurrence of Terrifying Nightmares after Few Days of Mirtazapine Use in Elderly Patients. Case Rep Psychiatry. 2023 Apr 4;2023:8843206. doi: 10.1155/2023/8843206. PMID: 37057036; PMCID: PMC10089773. 16: Maidwell-Smith A, Kirk C. Mirtazapine-induced neutropenic sepsis in an older person: a case report. J Med Case Rep. 2023 Apr 14;17(1):163. doi: 10.1186/s13256-023-03881-6. PMID: 37055872; PMCID: PMC10103480. 17: Hawkins M. A 9-year-old female with iron deficiency has severe periodic limb movements while taking mirtazapine for insomnia. J Clin Sleep Med. 2023 Jul 1;19(7):1369-1373. doi: 10.5664/jcsm.10580. Epub ahead of print. PMID: 37032615; PMCID: PMC10315591. 18: Jørgensen CK, Juul S, Siddiqui F, Horowitz MA, Moncrieff J, Munkholm K, Hengartner MP, Kirsch I, Gluud C, Jakobsen JC. The risks of adverse events with venlafaxine and mirtazapine versus 'active placebo', placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis. Syst Rev. 2023 Mar 30;12(1):57. doi: 10.1186/s13643-023-02221-5. PMID: 36991504; PMCID: PMC10061867. 19: Aldeeb RAE, Mahdy MAE, El-Nahas HM, Musallam AA. Design of mirtazapine solid dispersion with different carriers' systems: optimization, in vitro evaluation, and bioavailability assessment. Drug Deliv Transl Res. 2023 Sep;13(9):2340-2352. doi: 10.1007/s13346-023-01316-9. Epub 2023 Mar 20. PMID: 36940079; PMCID: PMC10382405. 20: Abdelhady R, Cavalu S, Saber S, Elmowafy R, Morsy NE, Ibrahim S, Abdeldaiem MSI, Samy M, Abd-Eldayem MA, Shata A, Elgharabawy RM. Mirtazapine, an atypical antidepressant, mitigates lung fibrosis by suppressing NLPR3 inflammasome and fibrosis-related mediators in endotracheal bleomycin rat model. Biomed Pharmacother. 2023 May;161:114553. doi: 10.1016/j.biopha.2023.114553. Epub 2023 Mar 17. PMID: 36934553.